Brevan Howard Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Brevan Howard Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Sell	94,638 -182,351	-66%	-$2.3M	0.01%	871
2025 Q4	$4.6M	Buy	276,989 +218,892	+377%	+$3.13M	0.05%	257
2025 Q3	$684K	Buy	58,097 +30,263	+109%	+$312K	﹤0.01%	1117
2025 Q2	$267K	Buy	+27,834	New	+$154K	﹤0.01%	1595
2025 Q1	–	Sell	-22,845	Closed	-$186K	–	1386
2024 Q4	$186K	Buy	+22,845	New	+$283K	﹤0.01%	922
2024 Q3	–	Sell	-18,792	Closed	-$194K	–	1361
2024 Q2	$194K	Buy	+18,792	New	+$194K	﹤0.01%	897

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ensign Peak Advisors

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return